Defining a Mutational Panel and Predicting the Prevalence of Cystic Fibrosis in Oman

Overview

Journal Sultan Qaboos Univ Med J

Specialty General Medicine

Date 2014 Aug 7

PMID 25097766

Citations 6

Authors

Uwe W Fass

Majid Al-Salmani

Said Bendahhou

Ganji Shivalingam

Catherine Norrish

Kallesh Hebal

Fiona Clark

Thomas Heming

Saleh Al-Khusaiby

Affiliations

Soon will be listed here.

Abstract

Objectives: Cystic fibrosis transmembrane conductance regulator (CFTR) mutations form distinct mutational panels in different populations and subgroups. The frequency of cystic fibrosis (CF) mutations and prevalence are unknown in Oman. This study aimed to elucidate the mutational panel and prevalence of CF for the North Al Batinah (NAB) region in Oman and to estimate the national prevalence of CF based on the carrier screening of unrelated volunteers.

Methods: The study included retrospective and prospective analyses of CF cases in the NAB region for 1998-2012. Genetic analysis of disease-causing mutations was conducted by screening of the entire coding sequence and exon-intron borders. The obtained mutational panel was used for the carrier screening of 408 alleles of unrelated and unaffected Omani individuals.

Results: S549R and F508del were the major mutations, accounting for 89% of mutations in the patient population. Two private mutations, c.1733-1734delTA and c.1175T>G, were identified in the patient cohort. Two carriers, one for F508del and another for S549R, were identified by screening of the volunteer cohort, resulting in a predicted prevalence for Oman of 1 in 8,264. The estimated carrier frequency of CF in Oman was 1 in 94. The carrier frequency in the NAB region was 3.9 times higher.

Conclusion: The mutational panel for the NAB region and the high proportion of S549R mutations emphasises the need for specific screening for CF in Oman. The different distribution of allele frequencies suggests a spatial clustering of CF in the NAB region.

Citing Articles

Diagnosis of cystic fibrosis: a high heterogeneity of symptoms and genotypes in a Brazil population.

Meneses D, Dos Santos F, Botelho A, Bispo L, Matos C, Propheta V BMC Pediatr. 2024; 24(1):422.

PMID: 38956483 PMC: 11218259. DOI: 10.1186/s12887-024-04891-z.

A comprehensive review of cystic fibrosis in Africa and Asia.

Bobbo K, Ahmad U, Chau D, Nordin N, Abdullah S Saudi J Biol Sci. 2023; 30(7):103685.

PMID: 37313453 PMC: 10258508. DOI: 10.1016/j.sjbs.2023.103685.

Prevalence and Characteristics of Cystic Fibrosis in Omani Children: A Multi-center Cross-sectional Study.

Al Oraimi S, Al Shidhani K, Al Harthi H, Al Sinani S, Al Busaidi N, Al Bimani M Oman Med J. 2022; 37(6):e444.

PMID: 36458240 PMC: 9627948. DOI: 10.5001/omj.2022.101.

Can We Justify Cystic Fibrosis Mutational Analysis among Omani Neonates?.

Al-Mendalawi M Oman Med J. 2022; 37(1):e344.

PMID: 35282428 PMC: 8898330. DOI: 10.5001/omj.2022.44.

Letter in Reply: Can We Justify Cystic Fibrosis Mutational Analysis among Omani Neonates?.

Balushi S, Al Balushi Y Oman Med J. 2022; 37(1):e345.

PMID: 35282426 PMC: 8907757. DOI: 10.5001/omj.2022.45.

References

Riordan J, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z . Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989; 245(4922):1066-73. DOI: 10.1126/science.2475911. View

Frossard P, Lestringant G, Girodon E, Goossens M, Dawson K . Determination of the prevalence of cystic fibrosis in the United Arab Emirates by genetic carrier screening. Clin Genet. 1999; 55(6):496-7. DOI: 10.1034/j.1399-0004.1999.550618.x. View

Daudin M, Bieth E, Bujan L, Massat G, Pontonnier F, Mieusset R . Congenital bilateral absence of the vas deferens: clinical characteristics, biological parameters, cystic fibrosis transmembrane conductance regulator gene mutations, and implications for genetic counseling. Fertil Steril. 2000; 74(6):1164-74. DOI: 10.1016/s0015-0282(00)01625-3. View

Hadj Fredj S, Fattoum S, Chabchoub A, Messaoud T . First report of cystic fibrosis mutations in Libyan cystic fibrosis patients. Ann Hum Biol. 2011; 38(5):561-3. DOI: 10.3109/03014460.2011.557090. View

Fanen P, Ghanem N, Vidaud M, Besmond C, Martin J, Costes B . Molecular characterization of cystic fibrosis: 16 novel mutations identified by analysis of the whole cystic fibrosis conductance transmembrane regulator (CFTR) coding regions and splice site junctions. Genomics. 1992; 13(3):770-6. DOI: 10.1016/0888-7543(92)90152-i. View

Sharer N, Schwarz M, Malone G, Howarth A, Painter J, Super M . Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med. 1998; 339(10):645-52. DOI: 10.1056/NEJM199809033391001. View

Rajab A, Patton M . A study of consanguinity in the Sultanate of Oman. Ann Hum Biol. 2000; 27(3):321-6. DOI: 10.1080/030144600282208. View

Rommens J, Iannuzzi M, Kerem B, Drumm M, Melmer G, Dean M . Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989; 245(4922):1059-65. DOI: 10.1126/science.2772657. View

Wright S . The genetical structure of populations. Ann Eugen. 2014; 15(4):323-54. DOI: 10.1111/j.1469-1809.1949.tb02451.x. View

10.

Brody A, Klein J, Molina P, Quan J, Bean J, Wilmott R . High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. J Pediatr. 2004; 145(1):32-8. DOI: 10.1016/j.jpeds.2004.02.038. View

11.

Banjar H . Geographic distribution of cystic fibrosis transmembrane regulator gene mutations in Saudi Arabia. East Mediterr Health J. 2002; 5(6):1230-5. View

12.

Kabra S, Kabra M, Shastri S, Lodha R . Diagnosing and managing cystic fibrosis in the developing world. Paediatr Respir Rev. 2006; 7 Suppl 1:S147-50. DOI: 10.1016/j.prrv.2006.04.218. View

13.

Hardy G . MENDELIAN PROPORTIONS IN A MIXED POPULATION. Science. 1908; 28(706):49-50. DOI: 10.1126/science.28.706.49. View

14.

Bobadilla J, Macek Jr M, Fine J, Farrell P . Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Hum Mutat. 2002; 19(6):575-606. DOI: 10.1002/humu.10041. View

15.

Quint A, Lerer I, Sagi M, Abeliovich D . Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. Am J Med Genet A. 2005; 136(3):246-8. DOI: 10.1002/ajmg.a.30823. View

16.

Sosnay P, Siklosi K, Van Goor F, Kaniecki K, Yu H, Sharma N . Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013; 45(10):1160-7. PMC: 3874936. DOI: 10.1038/ng.2745. View

17.

Ciofu O, Hansen C, Hoiby N . Respiratory bacterial infections in cystic fibrosis. Curr Opin Pulm Med. 2013; 19(3):251-8. DOI: 10.1097/MCP.0b013e32835f1afc. View

18.

Zielenski J, Rozmahel R, Bozon D, Kerem B, Grzelczak Z, Riordan J . Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics. 1991; 10(1):214-28. DOI: 10.1016/0888-7543(91)90503-7. View

19.

Ratbi I, Genin E, Legendre M, Le Floch A, Costa C, Cherkaoui-Deqqaqi S . Cystic fibrosis carrier frequency and estimated prevalence of the disease in Morocco. J Cyst Fibros. 2008; 7(5):440-3. DOI: 10.1016/j.jcf.2007.12.006. View

20.

Mathew P, Hamdan J, Nazer H . Cystic fibrosis presenting with recurrent vomiting and metabolic alkalosis. Eur J Pediatr. 1991; 150(4):264-6. DOI: 10.1007/BF01955527. View